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rine are infiltrated periarticularly during operation and via an 
intraarticular catheter postoperatively.
In the last few years, several studies supporting the ben-
efits of the LIA technique or the modified LIA technique in 
knee and hip arthroplasties have been published (Lombardi 
et al. 2004, Reilly et al. 2005, Andersen et al. 2007a, b, Par-
vataneni et al. 2007, Essving et al. 2009). However, there have 
only been 4 randomized controlled trials involving total knee 
arthroplasty (Busch et al. 2006, Vendittoli et al. 2006, Toftdahl 
et al. 2007, Andersen et al. 2008). Despite the great variabil-
ity in reported performance of the LIA technique, all studies 
found that there was effective postoperative analgesia compa-
rable with the standard for pain relief in TKA, the peripheral 
nerve block (Toftdahl et al. 2007). In contrast to the results of 
Kerr and Kohan, however, there was no evidence of any short-
ening of the hospital stay. 
We have previously reported on a double-blind RCT on uni-
compartmental knee arthroplasty (UKA) performed with min-
imally invasive technique, using the LIA technique by Kerr 
and Kohan peri- and postoperatively (Essving et al. 2009). We 
found that there was a shorter hospital stay, and lower mor-
phine consumption and pain intensity compared to placebo. 
Total knee arthroplasty (TKA) involves a greater degree of 
surgical  trauma  than  UKA  performed  using  the  minimally 
invasive technique, resulting in more severe pain intensity. We 
were therefore interested in assessing the efficacy of the LIA 
technique during TKA. 
The main purpose of the present study was therefore to eval-
uate whether the LIA technique would reduce morphine con-  technique would reduce morphine con-  would reduce morphine con-
sumption during the first 48 postoperative hours. Secondary 
endpoints were pain intensity, time to home readiness using 
well-defined discharge criteria, side effects, plasma concentra-
tions of local anesthetics, knee function, and patient satisfac-
tion. 
Background and purpose   Postoperative pain is often severe after 
total knee arthroplasty (TKA). We investigated the efficacy of the 
local infiltration analgesia (LIA) technique, both intraoperatively 
and postoperatively.
Methods   48 patients undergoing TKA were randomized into 2 
groups in a double-blind study. In group A, 400 mg ropivacaine, 
30 mg ketorolac, and 0.5 mg epinephrine were infiltrated periar-
ticularly during operation. In group P, no injections were given. 
21 h postoperatively, 200 mg ropivacaine, 30 mg ketorolac, and 
0.1 mg epinephrine were injected intraarticularly in group A, and 
the same volume of saline was injected in group P. All patients 
were followed up for 3 months.
Results   Median morphine consumption was lower in group A 
during the first 48 h: 18 (1–74) mg vs. 87 (36–160) mg in group P. 
Postoperative pain was lower at rest in group A during the first 
27 h, and on movement during the first 48 h, except at 21 h. Time 
to fulfillment of discharge criteria was shorter in group A than in 
group P: 3 (1–7) vs. 5 (2–8) days. Patient satisfaction was higher 
in group A than in group P on days 1 and 7. The unbound venous 
blood  concentration  of  ropivacaine  was  below  systemic  toxic 
blood concentrations.
Interpretation   The local infiltration analgesia (LIA) technique 
provides excellent pain relief and lower morphine consumption 
following TKA, resulting in shorter time to home readiness and 
higher patient satisfaction. There were few side effects and sys-
temic LA concentrations were low.
 
Postoperative pain is usually severe after knee arthroplasty 
(Wang et al. 2002). In an attempt to improve pain relief, a local 
infiltration analgesia (LIA) technique was recently developed 
by Drs Kerr and Kohan in Sydney, Australia (Kerr and Kohan 
2008). A  long-acting  local  anesthetic  (LA;  ropivacaine),  a 
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Patients and methods
The study protocol was approved by the regional ethics com-
mittee (September 6, 2006; Dnr 2006/211) and the Swedish 
Medical Products Agency, and was conducted in accordance 
with the Declaration of Helsinki. It was also registered with 
ClinicalTrials.gov (identifier: NCT00799175).
78 consecutive patients scheduled for total knee arthroplasty 
(TKA) because of osteoarthritis were screened for eligibility. 
The inclusion criteria were: age 20–85 years, ASA I–III, and 
normal  preoperative  mobility.  Exclusion  criteria  included 
known allergy or intolerance to one of the study drugs, seri-
ous liver-, heart- or renal disease, inflammatory joint disease, 
chronic pain, or any bleeding disorder. 
Randomization and blinding
Of the 78 patients assessed for eligibility, 30 were excluded 
prior to randomization; see flow chart for details (Figure 1). 
Written  informed  consent  was  obtained  from  each  patient 
before the start of the study. Surgery was performed at the 
Department  of  Orthopedics,  Örebro  University  Hospital 
during April 2007 through September 2008 and patients were 
followed up for 3 months after surgery. 
The  hospital  pharmacy  randomized  the  patients  into  2 
groups with 24 patients in each, using computer-generated 
randomized  numbers.  Group A  (Active)  received  a  multi-
modal  injection  intra-  and  postoperatively  while  group  P 
(Placebo) did not receive any injection intraoperatively and 
Surgery
All  operations  were  performed  using  a  standard  medial 
parapatellar approach. All patients received an AGC prosthe-
sis (Biomet, Warsaw, IN). A tourniquet was used in all patients 
and no drains were left in the knee joint after the operation. A 
compression bandage and ice packs were applied around the 
knee joint during the first 6 h.
Pain management
In group A, 400 mg ropivacaine, 30 mg ketorolac, and 0.5 
mg epinephrine (total volume 166 mL) were infiltrated by the 
surgeon into the soft tissues periarticularly during the opera-
tion in the following way: 300 mg ropivacaine, 30 mg ketoro-
lac, and 0.5 mg epinephrine were mixed together to a total 
volume of 116 mL. Before inserting the prosthesis, 40–50 mL 
of the solution was injected into the posterior capsule. After 
the prosthesis was cemented in place, the rest of the solu-
tion was injected into the deep tissues around the ligaments, 
the capsule incision, and the synovium. In this way, all tis-
sues that were traumatized received the analgesic solution. 
Before closing the skin, 50 mL ropivacaine (100 mg) without 
epinephrine or ketorolac was injected into the subcutaneous 
tissue. In group P, no injections were given. All patients had 
a tunnelled intraarticular multihole 20-G catheter placed at 
the end of the operation by the surgeon. A patient-controlled 
analgesia (PCA) pump with morphine (1-mg bolus and 6-min 
lockout time) was connected intravenously, which was used 
as rescue medication by all patients. All patients received 1 g 
Figure 1.  Flow chart for the study.
Excluded (n = 30) 
Refused to participate (n = 9) 
Reumatoid arthritis (n = 1) 
Bleeding disorder (n = 2) 
Chronic pain (n = 1) 
Intolerance to study drugs (n = 1) 
Liver, heart or renal disease (n = 2)
Others (n = 14) 
Excluded (n = 1) 
Disorientation 
          No injection  400 mg ropivacaine (160 mL) 
30 mg ketorolac (1 mL) 
0.5 mg epinephrine (5 mL) 
          Saline (22 mL) 
              (n = 23)
200 mg ropivacaine (20 mL) 
30 mg ketorolac (1 mL) 
0.1 mg epinephrine (1 mL) 
             (n = 24)
Intraoperatively (soft 
tissue injection) 
21 h postoperatively 
(intraarticularly via 
catheter) 
Assessed for eligibility 
(n = 78) 
Randomized 
(n = 48) 
Group A (n = 24)  Group P (n = 24) 
received  a  saline  injection  postopera-
tively  as  detailed  below.  On  the  day 
before or on the morning of surgery, the 
surgeon  called  the  hospital  pharmacy 
to  receive  the  group  randomization. 
The patients, the 2 study investigators, 
the  study  physiotherapist,  and  all  the 
staff  concerned  with  the  postoperative 
care of the patients were blinded to the 
group randomization. Since the operat-
ing surgeons were not blinded, they did 
not take any part in the patient care after 
completion of the operation.
Anesthesia
All patients received diazepam (10 mg) 
orally 1 h before planned surgery and 
all  operations  were  performed  under 
general  anesthesia.  Cloxacillin  (1  g) 
was given intravenously before surgery 
and at 8, 16, and 24 h postoperatively. 
Dalteparin (5,000 IU) was administered 
subcutaneously  once  each  evening  for 
10 days, starting on the evening before 
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paracetamol orally 4 times a day, starting on the morning of 
the operation. After 21 h, 200 mg ropivacaine, 30 mg ketoro-
lac, and 0.1 mg epinephrine in total volume of 22 mL were 
injected intraarticularly via the catheter in group A and a simi-
lar volume of saline was injected in group P. Pain assessments 
were made by using a 100-mm VAS. At 24 h, if pain at rest 
was VAS < 40 mm over a 2-h period, the PCA pump was dis-
continued and paracetamol (1 g) and tramadol (100) mg orally 
were given up to 4 times daily as required. The intraarticular 
catheter was removed after 24 h and the tip of the catheter was 
sent for culture.
Mobilization and home discharge
The first attempt at mobilization was made on the first post-
operative morning, 1 h after the intraarticular injection. The 
patients were encouraged to stand up and to walk 2–3 steps, 
and they were discharged when they fulfilled the discharge 
criteria (see below). Following discharge home, all patients 
were asked to complete a questionnaire regarding postopera-
tive pain on days 1, 3, and 14.
Outcome measures: primary endpoint
Analgesic  consumption.  PCA-morphine  consumption  was 
recorded  during  0–24,  24–48,  and  0–48  h  postoperatively. 
Oral analgesic consumption (tramadol) was recorded during 
0–24, 24–48, and 0–48 h. Total analgesic consumption 0–48 h 
postoperatively was calculated by converting oral tramadol to 
the equivalent dose of intravenous morphine, i.e. 100 mg tra-
madol orally was equivalent to 10 mg morphine intravenously 
(Silvasti et al. 2000).
Outcome measures: secondary endpoints
Pain. Pain assessment (VAS) was made preoperatively and at 
3, 6, 12, 21, 22 (i.e. 1 h after test drug injection in the knee 
catheter), 27, and 48 h, and also on days 3 and 14, and at 3 
months postoperatively. Pain was assessed both at rest and on 
flexion of the knee by 60 degrees.
Hospital stay. The time to fulfillment of discharge criteria 
(home readiness) was recorded by a physician and the study 
physiotherapist who were unaware of the group randomiza-
tion. The discharge criteria were: mild pain (VAS < 30 at rest) 
sufficiently controlled by oral analgesics, ability to walk with 
elbow crutches, ability to climb 8 stairs, ability to eat and 
drink, and no evidence of any surgical complications. Length 
of hospital stay (LOS) was recorded as actual time to home 
discharge once the home discharge criteria were fulfilled (day 
0 = the day of operation). Differences between the two could 
result from delayed discharge for administrative or social rea-
sons.
Surgical outcome. Maximum knee extension and flexion 
were assessed preoperatively, at 24 h, 48 h, on day 3, at dis- , 48 h, on day 3, at dis- 3, at dis-  at dis-
charge, and after 3 months postoperatively. Timed up and go 
(TUG) test (Podsiadlo and Richardson 1991) was assessed 
preoperatively and postoperatively after 48 h, on days 3, 7 and 
14, and after 3 months. Values of < 20 seconds indicate that 
the patient is indepentently mobile. An evaluation of patient 
satisfaction  was  done  using  a  4-grade  verbal  rating  scale 
(excellent = 4, good = 3, inadequate = 2, poor = 1) during 
the first 24 postoperative hours and after 7 days. Oxford knee 
score was determined preoperatively, and at 2 weeks and 3 
months  postoperatively.  Oxford  knee  score  is  a  validated 
12-item knee questionnaire that scores patients from 12 (the 
best possible) to 60 (the worst possible) (Jahromi et al. 2004). 
EuroCol (EQ-5D) questionnaire was collected preoperatively 
and postoperatively at 3 months. EuroCol (EQ-5D) is a stand-
ardized instrument for use as a measure of health outcome 
(Fransen and Edmonds 1999). It provides a single index value 
from 0 to 1 where 0 represents poor health and 1 represents 
perfect health.
Adverse effects. All complications and adverse events were 
registered intraoperatively and postoperatively, and also after 
discharge. Any hospital re-admissions during the 3-month fol-
low-up period postoperatively were also recorded. 
Plasma concentrations of ropivacaine 
In a sub-study in 8 patients, done prior to the main study, 
the LIA technique was performed in a similar way to that 
described earlier. Venous blood (7 mL) was taken in heparin-
ized tubes postoperatively after 30, 60, 90, 120, and 180 min 
and just before and after the catheter injection at 30, 60, 90, 
120, and 180 min. Total and free concentrations of ropivacaine 
were analyzed using chromatography with a Zorbax SB-C18 
column.
Statistics
A power analysis was done before the start of the study using 
morphine consumption over 48 hours postoperatively as the 
primary endpoint. In an earlier study on total knee arthro-
plasties (Axelsson et al. 2005), the mean morphine consump-
tion over 48 hours postoperatively was 64.6 (SD 36.3) mg in 
the placebo group. The aim of this study was to investigate 
whether the LIA technique could reduce the morphine con-
sumption by 50% to 32 mg. With an a of 0.05 and b of 0.2, we 
calculated that 24 patients would be required in each group if a 
non-parametric method was used. The number of patients for 
the sub-study was calculated to be 8.
The Mann-Whitney U test was used for the analysis of the 
primary  endpoint  (morphine  consumption)  since  we  found 
that the data were not normally distributed. Mann-Whitney U 
test was used to assess pain scores and the Bonferroni-Holm 
method was used to correct for multiple measures. Hospital 
stay, time to fulfill discharge criteria, knee function scores, and 
patient satisfaction scores were also analyzed using the Mann-
Whitney U test. Dichotomous data were analyzed using the 
chi-squared test or Fisher’s exact test, as appropriate. Values 
of p < 0.05 were considered to be statistically significant.Acta Orthopaedica 2010; 81 (3): 354–360  357
Table 1. Demografic data and duration of surgery. 
Values are mean (SD)
  Group A  Group P
   
No. of females/males    13/11    13/11
Age, years    72 (9)    70 (9)
Weight, kg    82 (14)    81 (10)
Height, cm  168 (9)  169 (8)
Body mass index    29 (5)    28 (3)
ASA, I / II / III  7 / 17 / 0  5 / 18 / 1
Operation time, min    93 (20)    87 (19)
   
Group A (active): intraoperative and postoperative 
injections.
Group P (placebo): no intraoperative or postop-
erative injections.
ASA physical status I: normal health; II: systemic 
disease with no limited activity; III: systemic dis-
ease with limited activity.
Table 2. Consumption of analgesics
  Group A  Group P  p-value
  median (range)  median (range)
Morphine i.v. (mg)
  0–24 h    17 (1–74)    65 (36–131)  < 0.001
  24–48 h    0.5 (0–17)    22 (0–52)  < 0.001
  0–48 h    18 (1–74)    87 (36–160)  < 0.001
Tramadol orally (mg) 
  0–24 h      0 (0–200)      0 (0–100)  0.01
  24–48 h  375 (0–400)  200 (0–400)  0.04
  0–48 h  400 (0–500)  200 (0–500)  0.008
Total analgesics a (mg) 
  0–48 h    54 (4–114)  109 (37–211)  < 0.001
         
a Total analgesic consumption was calculated by converting oral 
tramadol to the equivalent dose of intravenous morphine 
(100 mg tramadol orally  =  10 mg morphine intravenously).
Figure 2. Postoperative pain at rest. VAS scores are presented as median and interquar-
tile range (IQR). a p < 0.001 (3, 6, and 12 h); p = 0.005 (21 h); p = 0.003 (22 h); p = 0.002 
(27 h). 
Results
Patients
One of the 48 randomized patients in group 
P  became  disoriented  postoperatively  and 
could not continue the study. Thus, 47 of the 
48 randomized patients completed the study. 
Patient  characteristics  were  similar  in  both 
groups (Table 1). 
Primary endpoint
Analgesic  consumption.  Median  morphine 
consumption during the first 48 h postopera-
tively was lower in group A than in group P: 
18 (1–74) mg vs. 87 (36–160) mg (p < 0.001), 
i.e. there was a median difference of 69 (95% 
CI: 47–86) mg (Table 2). The proportion of 
patients  who  requested  ≥  5  mg  morphine 
during the first 24 h was significantly less in 
group A than in group P (0/23 vs. 10/24) (p 
< 0.01). Median total analgesic consumption 
(tramadol  +  morphine)  during  the  first  48 
postoperative hours was 54 (4–114) mg and 
109 (37–221) mg, respectively (p < 0.001).
Secondary endpoints
Pain relief. At rest, median VAS pain score 
was statistically significantly lower in group 
A than in group P at 3, 6, 12, 21, 22, and 27 
h (Figure 2). 
On movement, median VAS pain score was 
statistically  significantly  lower  in  group A 
than in group P at 3, 6, 12, 22, 27, and 48 h 
(Figure 3).  
Hospital stay. Median time to home readi-
ness was shorter in group A than in group P, 3 
Figure 3. Postoperative pain on movement. VAS scores are presented as median and 
interquartile range (IQR). a p < 0.001 (3, 6, 12, and 22 h); p = 0.005 (27 h); p = 0.01 (48 h).358  Acta Orthopaedica 2010; 81 (3): 354–360
(1–7) vs. 5 (2–8) days (p = 0.03). The median length of hospi-
tal stay (LOS) was shorter in group A than in group P, 4 (2–8) 
days vs. 6 (3–10) days, but this was not statistically significant 
(p = 0.06)
Surgical outcomes. There was a difference in knee flexion 
between group A and group P at 24 h postoperatively; 90 
(60–105) vs. 60 (30–85) degrees (p < 0.001) and 48 h: 75 
(50–105) vs. 60 (40–90) degrees (p = 0.003) (Table 3), but 
no statistically significant differences were found at 3 days 
and 3 months postoperatively. No significant differences were 
found between the groups in knee extension, except at dis-
charge. The TUG-test did not show any differences between 
the groups postoperatively.
Patient satisfaction scores differed between the groups on 
day 1 (p < 0.001) and on day 7 (p = 0.02). Oxford Knee Score 
and EQ-5D value were similar postoperatively, at 14 days, and 
at 3 month in both groups (Table 3).
these patients showed any clinical evidence of systemic LA 
toxicity.
Discussion
The total consumption of analgesics was lower in the LIA 
group than in the placebo group, which was our primary end-
point, during the 48-h test period. This is consistent with our 
previous study on unicompartmental knee surgery (Essving et 
al. 2009) and also the findings of others using a similar (but 
modified) technique during TKA (Busch et al. 2006, Vendit-
toli et al. 2006, Andersen et al. 2008). Although TKA would 
be expected to be more painful than unicompartmental knee 
surgery, we found that both analgesic consumption and pain 
intensity in the LIA groups were similar between the stud-
ies. This may be because we increased the dose of ropivacaine 
Table 3. Mobilization and patient satisfaction
Outcome  Group A    Group P    p-value
  median (range)  n  median (range)  n
Knee extension (degrees) 
  Preop.    5 (0–30)   23    5 (0–20)   19   
  24 h postop.  10 (0–20)   24  10 (0–20)   19  0.4 
  48 h postop.  10 (0–15)   23  10 (0–15)   21  0.4 
  Discharge  10 (0–10)   24  10 (5–10)   23  0.01 
  3 days postop.  10 (0–15)   22  10 (0–15)   22  0.4 
  3 months postop.    5 (0–10)  20    5 (0–15)  23  0.6
Knee flexion (degrees) 
  Preop.  120 (90–153)   23  120 (100–135)   19   
  24 h postop.    90 (60–105)   24    60 (30–85)   23  < 0.001 
  48 h postop.    75 (50–105)   23    60 (40–90)   22  0.003
  Discharge    85 (60–115)   24    75 (60–100)   23  0.2 
  3 days postop.    75 (60–110)   22    62 (45–90)   22  0.09 
  3 months postop.  112 (100–125)   20  110 (90–130)   22  0.3
TUG test (seconds)
  Preop.  10 (6–26)  21    9 (6–28)   17   
  48 h postop.  22 (10–51)   15  27 (8–35)     8  na a 
  3 days postop.  18 (9–49)  16  20 (8–80)  12  na a
  7 days postop.  18 (10–48)  24  17 (7–65)  21  0.8
  14 days postop.  14 (7–42)  22  10 (6–25)  22  0.5
  3 months postop    8 (6–16)  20    7 (5–19)  23  0.8 
Patient satisfaction 
  1 day postop.  4 (2–4)   23  3 (1–4)   20  < 0.001 
  7 days postop.  3 (1–4)   23  3 (1–4)   20  0.02 b
Oxford knee score 
  Preop.  39 (26–49)   23  40 (27–42)   20   
  14 days postop.  33 (18–42)   20  32 (25–45)   21  0.9 
  3 months postop.  16 (12–37)   20  16 (12–28)   23  0.8
EQ-5D 
  Preop  0.66 (0.06–0.80)  23  0.20 (0.03–0.73)   23   
  3 months postop.  1 (0.59–1)   21  1 (0.69–1)   23  1
n: number of patients who participated varied depending on patients’ ability to cooperate.
TUG test: Timed up and go test.
a na:  not applicable. No statistical calculations were done due to the small number of 
   patients in each group.
b Patient satisfaction: Excellent = 4, good = 3, inadequate = 2, poor = 1. 
  In group A, 20/23 scored 3–4 as compared to 12/20 in group P 7 days postoperatively.
Oxford knee score: 12 (the best possible) to 60 (the worst possible).
EQ-5D health outcome: 1 = perfect health; 0 = poor health. 
Table  4.  Side  effects.  Values  are  number  of 
patients in each category 
  Group A  Group P  p-value
   (n = 24)   (n = 23) 
   
Nausea 
  0–24 h  9  16  0.03
  24–48 h  4  8  0.2
Vomiting
  0–24 h  5  9  0.2
  24–48 h  1  3  0.4 
Pruritus 
  0–24 h  1  9  0.004 
  24–48 h  0  6  0.009 
Sedation 
  0–24 h  0  5  0.02 
  24–48 h  0  1  0.5
Adverse  effects.  There  were  no  major 
surgical complications. There was a lower 
incidence  of  nausea,  pruritus,  and  seda-
tion in group A than in group P (Table 4). 
There  were  3  positive  cultures  from  the 
catheter tips, all with isolated coagulase-
negative Staphylococcus, 2 in group A and 
1 in group P. No antibiotics were given and 
no clinical signs of infection were found 
during the follow-up period. None of the 
patients  were  re-admitted  to  the  hospital 
for  any  adverse  effects  or  complications 
during the 3-month follow-up period. We 
did not find any deep venous thrombosis or 
insufficient wound heeling.
Plasma  concentrations  of  ropivacaine. 
The individual maximum unbound venous 
plasma concentration of ropivacaine varied 
from 0.032 µg/mL to 0.12 µg/mL in the 
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injected periarticularly from 200 mg to 400 mg in the pres-
ent study. The pain intensity measured by VAS was generally 
lower in the LIA group than in the placebo group during the 
first 48 h, specifically pain on movement. This would further 
confirm that local infiltration of analgesics periarticularly is 
efficacious and can therefore be recommended for analgesia 
following TKA. However, does better postoperative analgesia 
also translate into improved patient outcome? 
We  measured  several  patient  outcomes  over  a  3-month 
period  in  order  to  determine  whether  improved  analgesia 
also gives better outcome for the patient. Thus, patient sat-
isfaction,  which  is  a  direct—though  crude—measure  of  a 
subjective feeling of quality of care, was higher in patients in 
the LIA group on days 1 and 7 postoperatively. Surgical out-
come, measured as the degree of knee flexion postoperatively, 
was also greater in the LIA group than in the placebo group, 
which could have been an indirect result of better analgesia 
in this group of patients. Outcome measures were better in 
the LIA group only in the early period, however, before home 
discharge. Taken together, these results indicate that patients 
receiving local infiltration analgesia feel subjectively better 
and are objectively better in the early postoperative period 
than those not receiving it. Thus, the next question is whether 
these improved patient outcomes also lead to cost reduction 
for the healthcare system.
Although we did not measure direct costs for patients or 
for the healthcare system, we did measure the time taken to 
achieve discharge criteria and also length of hospital stay. 
We found that time to home readiness in the LIA group was 
shorter than in the placebo group by 2 days, a statistically 
significant  and  a  clinically  relevant  reduction.  The  actual 
length of hospital stay was shorter, but the difference did not 
reach statistical significance and was similar to the results of 
other authors using a similar technique in patients undergoing 
TKA (Busch et al. 2006, Vendittoli et al. 2006, Toftdahl et al. 
2007). Although home readiness can be affected by several 
factors, we used objective and clearly defined discharge cri-
teria that we have described previously (Essving et al. 2009). 
In addition, the personnel determining home readiness were 
blinded regarding the treatment arm, thus reducing bias. The 
slightly longer length of hospital stay compared to the time 
to achieve discharge criteria was the result of non-medical 
considerations such as the absence of a relative to take care of 
the patient at home or delay in hospital discharge for admin-
istrative reasons. 
Although there were several outcome variables that were 
in favor of the LIA technique, we did not find any statisti-
cally significant differences in certain other parameters. Thus, 
there were no differences between the groups in the TUG test, 
the Oxford knee score, or in the EQ5D at the measurement 
points described earlier. There could be several reasons for the 
absence of such differences. Health-related quality of life as 
determined by the EQ5D and Oxford knee score is a crude 
measure of ADL function, and is therefore heavily weighed 
down by factors other than early postoperative pain. Thus, 
when we measured these parameters after 14 days, there was 
no difference in pain intensity between the groups; thus, we 
did not find any differences in the EQ5D and the Oxford knee 
score. 
An important question is whether a catheter should be placed 
intraarticularly, exposing the patient to the risk of infection. In 
order to answer this question, a risk-benefit analysis must be 
done. The benefit that the patient obtained was the possibility 
of re-injection of analgesic drugs after 21 h in order to pro-
long analgesia and improve patient outcome. The pain relief 
achieved as a consequence of re-injection the following day 
after the operation was statistically significant and clinically 
relevant when compared to pain intensity between the groups, 
specifically pain on movement—a benefit that persisted for up 
to 48 h. This, taken together with the fact that morphine con-
sumption was considerably reduced in the LIA group from 24 
h to 48 h would suggest that the catheter prolonged the analge-
sia after the first day. However, it would be interesting to study 
this benefit longitudinally to better understand the benefits of 
leaving the catheter in situ after the operation. There was no 
evidence of any postoperative infections or infection after a 
3-month follow-up, which indicates that the risk of infection, 
if any, was small. However, this study is small and more stud-
ies should be done in order to evaluate the risk of infection. It 
is also important to emphasize that in our study, the catheters 
were placed under aseptic conditions by the surgeon at the end 
of the operation; bacterial filters were used, which is a rou-
tine with other catheter techniques, and the investigators who 
injected drugs after 21 h did so under aseptic conditions. We 
believe that, if appropriately and correctly done, the benefit 
of retaining a catheter intraarticularly outweighs the potential 
risk of complications and until proved otherwise, catheters 
may be inserted into the knee joint following TKA, albeit 
under antibiotic protection.
Another  question  that  arises  is  whether  the  dose  of  LA 
injected  periarticularly  may  produce  toxic  concentrations 
through  systemic  absorption.  Indeed,  we  did  inject  higher 
doses than in our previous study due to the more extensive 
surgery. The total dose of ropivacaine injected was, however, 
below the maximum dose recommended by the manufactur-
ers. Furthermore, we confirmed that the maximum concen-
tration of LA seen in any of the 8 patients in whom plasma 
concentration was measured was far below the known toxic 
concentrations in humans (Knudsen et al. 1997) and corre-
sponded well with findings from other authors (Busch et al. 
2006). In addition, none of the patients had any evidence of 
systemic LA toxicity, confirming that these doses are safe 
when injected periarticularly.
Finally, the safety of ketorolac injected intraarticularly can 
be questioned in view of some evidence, specifically from 
animal studies, of the risk of delay in bone healing (Meunier 
and Aspenberg 2006). We cannot answer this question, as the 
follow-up period was only 3 months in our patients. 360  Acta Orthopaedica 2010; 81 (3): 354–360
In summary, our findings provide strong evidence that the 
LIA technique is effective and safe, specifically for pain man-
agement in the early postoperative period, and it can therefore 
be recommended following TKA. Future studies should focus 
on the drugs and doses that should be used in the LIA mixture 
and on the length of time that the catheter should remain in 
situ. 
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